Maynard Um
-
-
-
-
-
-
-
Spyre (SYRE) PT Raised to $107 at Stifel
-
-
-
-
-
-
-
Spyre (SYRE) PT Raised to $80 at Wedbush
-
-
-
-
-
-
-
Spyre reports positive trial results for ulcerative colitis drug SPY001
-
-
-
-
-
-
-
Spyre Therapeutics expects six trial readouts in 2026
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Spyre (SYRE), 'remains one of our Top Picks'
-
-
-
-
-
-
-
Spyre Therapeutics, Inc. (SYRE) Tops Q1 EPS by 24c
-
-
-
-
-
-
-
Spyre Therapeutics (SYRE) Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
-
418,483 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

